Het Spaarne Gasthuis is een ziekenhuis in de Hoofddorpse wijk Floriande aan de N201 en N205. Het ziekenhuis is in 2004 geopend ter vervanging van het oude ziekenhuis, de Mariastichting, in Haarlem. Er is een nevenvestiging in Heemstede en er zijn poliklinieken in Hillegom en Lisse.

During the past decade, Spaarne Gasthuis conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 10 clinical trials were completed, i.e. on average, 21.7% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 9 clinical trials were completed. i.e. 64.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Spaarne Gasthuis" #1 sponsor was "The Netherlands Cancer Institute" with 8 trials, followed by "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 7 trials sponsored, "Pfizer" with 4 trials sponsored, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 3 trials sponsored and "Borstkanker Onderzoek Groep" with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Spaarne Gasthuis" #1 collaborator was "Borstkanker Onderzoek Groep" with 4 trials as a collaborator, "Spaarne Gasthuis" with 4 trials as a collaborator, "Roche Pharma AG" with 3 trials as a collaborator, "ZonMw: The Netherlands Organisation for Health Research and Development" with 3 trials as a collaborator and "Amphia Hospital" with 2 trials as a collaborator. Other collaborators include 98 different institutions and companies that were collaborators in the rest 95 trials.

According to Clinical.Site data, the most researched conditions in "Spaarne Gasthuis" are "Breast Cancer" (6 trials), "Colorectal Cancer" (4 trials), "Colon Cancer" (2 trials), "Multiple Myeloma" (2 trials) and "NHL" (2 trials). Many other conditions were trialed in "Spaarne Gasthuis" in a lesser frequency.

Most popular intervention types in "Spaarne Gasthuis" are "Drug" (47 trials), "Other" (11 trials), "Procedure" (7 trials), "Biological" (6 trials) and "Device" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Bevacizumab" (4 trials), "Cyclophosphamide" (3 trials), "Dexamethasone" (3 trials) and "Enzalutamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Spaarne Gasthuis" are 53 trials for "All" genders, 7 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 34 active trials in "Spaarne Gasthuis". 1 are not yet recruiting, 7 are recruiting, 25 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 26 completed trials in Spaarne Gasthuis, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Spaarne Gasthuis, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 11 trials that are defined as “Not Applicable".